HealthTronics, a provider of urological products and services, has signed a definitive merger agreement with Endo Pharmaceuticals pursuant to which Endo will acquire HealthTronics.

Under the terms of the merger agreement, Endo expects to commence an all cash tender offer to acquire all of the outstanding shares of HealthTronics common stock for approximately $223m or $4.85 cash per HealthTronics share plus the assumption of debt.

Reportedly, following completion of the tender offer, a wholly-owned subsidiary of Endo will merge into HealthTronics and the HealthTronics’ shares which are not acquired in the tender offer will convert into the right to receive the same consideration as paid in the tender offer.

James Whittenburg, president and CEO of HealthTronics, said: “Together with Endo we will be better positioned to fulfill our mission of bringing services and technologies that both improve patient care and enhance physician practice economics, thus enhancing the value of the channel HealthTronics has established with leading urologists.”

Dave Holveck, president and CEO of Endo, said: “Beyond diversifying our revenue base, the acquisition of HealthTronics will further position Endo as a preferred healthcare provider of multiple medical solutions and delivery mechanisms that help improve patient outcomes in the field of Urology.

“The strategic acquisition will elevate Endo from a pharmaceutical company to a diversified partner to physicians and payers in the treatment and diagnosis of urological and pain-related conditions. We believe this deal will also enhance our ability to deliver long-term, sustainable growth for our shareholders in an evolving healthcare environment.”

HealthTronics is a urology company with product portfolio of a full line of urology equipment and products, including lithotripters, surgical lasers for treatment of BPH, and anatomical pathology services.